Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980677 | 0.92 | FKBP1A (0.50) | FKBP1APREPKLK7KLK5ACE | |
| SCHEMBL993838 | 0.85 | PRCP (0.46) | FKBP1APREPKLK7KLK5ACE | |
| SCHEMBL993837 | 0.85 | PRCP (0.46) | FKBP1APREPKLK7KLK5ACE | |
| SCHEMBL14865075 | 0.82 | FKBP1A (0.60) | FKBP1APREPKLK7KLK5KDM4E | |
| SCHEMBL19442013 | 0.81 | FKBP1A (0.53) | FKBP1APREPKLK7KLK5ACE | |
| SCHEMBL7326760 | 0.78 | FKBP1A (0.66) | FKBP1APREPKLK7KLK5KDM4E | |
| SCHEMBL16272917 | 0.78 | FKBP1A (0.66) | FKBP1APREPKLK7KLK5KDM4E | |
| SCHEMBL31257539 | 0.77 | FKBP1A (0.72) | FKBP1APREPKLK7KLK5KDM4E | |
| SCHEMBL6788139 | 0.76 | FKBP1A (0.64) | FKBP1APREPACE | |
| SCHEMBL11940447 | 0.76 | FKBP1A (0.64) | FKBP1APREPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | FKBP1A 412/4885PREP 2238/4885KLK7 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.